Slide 1: Soligenix
(SOLIGENIX OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the comments of our management related thereto contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” "intends,
Slide 3: Company Highlights
Company Highlights » Diverse pipeline with nine (9) potential value drivers in development © Innovative products addressing high unmet medical needs o Experienced management and Board of Directors o Expertise in specialized development areas of GI, cancer supportive care and biodefense © Potential f
Slide 4: Development Candidates
Development Candidates BioTherapeutics SGX842 Oral Mucositis in Head & Neck Cancer SGX203 Pediatric Crohn's Disease Radiation Enteritis n a ) Ph. 2b start 1H 2014" = ed Chronic GI Graft vs. Host Disease (GVHD) | ” PE 2 data 3H 201¢* FAST TRACK DESIGNATION Ph. 2 data 2H 2014" ORPHAN/FAST TRACK DESIGN
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers ss) SGX201 2H: P2b start in Radiation Enteritis BHP dain — [ee] evn) Esa Son <a a 2H: Preclinical VeloThrax animal data anthrax = Di tal iis ita a esto sabe SOLIGENIX 2H: Potential grant! 1H: Canine data. | 2H: NHP data contract award(s)
Slide 6: Experienced Management and Board of Directors
Experienced Management and Board of Directors Christopher J. Schaber. MS, PhD Prosident & CEO Robert Brey, PhD Chisf Scientific Financial Offic 23 years of experience Discovery Laboratories (COO) Acute Therapeutics (Co-Founder) Ohmeda PPD The Liposome Company Wyeth Ayerst 29 years of experience Lede
Slide 7: BioTherapeutics
BioTherapeutics
Slide 8: BioTherapeutics Business Segment
BioTherapeutics Business Segment Our commercial target is inflammation (Oral Mucositis in & Neck Oral BOP. Soligenix BioTherapeutics Segment
Slide 9: SGX94: Regulating the Innate Defense System
SGX94: Regulating the Innate Defense System First responder to infection and tissue injury Innate Mobilizes anti-infective and tissue healing factors Immunity Mobilizes adaptive immunity May cause excessive inflammatory response Synthetic 5 amino acid Innate Defense Regulator (IDR) targeting Sequest
Slide 10: Oral Mucositis — Multi-Factorial Disease
Oral Mucositis — Multi-Factorial Disease Debilitating side effect of cancer chemotherapy and / or radiotherapy Massive ulceration of the mouth, tongue, soft palate and oropharynx Results in severe pain, inability to eat, reduced cancer treatment tolerance and significant increases in resource use an
Slide 11: Radiation-Induced Mucositis
Radiation-Induced Mucositis GOLD STANDARD Animal Model of Mucositis related to H&N Cancer + Decreased duration of mucositis by ~50% + Decreased peak severity from 3.4 to 3.0 50 ° u 3 40 46% reduction 8 30 P< 001 oO a 20 a x 10 Cy) Vehicle SGX942 Oral Mucositis Induced in Hamsters by Fractionated Rad
Slide 12: Chemo-Induced Mucositis
Chemo-Induced Mucositis PROTECTS against chemotherapy damage PROTECTS ALL mucosal tissue Duration of Severe Oral Mucositis Clinical Endoscopy Score a = £ a Day 4 Day 7 8 + 2.0: é z ® : = é 1.5: 3 2 e § 10 }ps.05 a > a = £ § 0.5: _ — ~ = g g 2 Gi x = 0.0: VEHICLE SGX942 MH Vehicle SGX942 Vehicle SGX9
Slide 13: SGX942 for Oral Mucositis
Phase 1 Clinical Trial Market Opportunity Development Plan SGX942 for Oral Mucositis Proprietary composition administered as 4-min IV infusion — short plasma half-life and rapid tissue penetration Phase 1 single and multiple ascending dose, double-blind, placebo-controlled study in 84 healthy volunt
Slide 14: SGX942 — Other Development Targets
SGX942 — Other Development Targets Multiple potential targets in infectious disease and biodefense with opportunity for non-dilutive funding to support development Target Indication Potential Application (s) | Potential Funding | Summary and Potential Next Steps Vaccine Adjuvant Biodefense; infectio
Slide 15: Oral Beclomethasone 17,21-Dipropionate
Oral Beclomethasone 17,21-Dipropionate $GX201, SGX203, orBec® and OrbeShield™ are all independent product opportunities based on our orally administered proprietary formulation technology with beclomethasone 17,21-dipropionate (BDP) Each enables potent, topical corticosteroid effect to treat Gl infl
Slide 16: SGX203 for Pediatric Crohn's Disease
$SGX203 for Pediatric Crohn’s Disease Two tablet proprietary formulation of immediate and delayed release BDP Designed to treat inflammation throughout the Gi tract Positioned as a corticosteroid option with less toxicity than the current standard systemic steroid therapy — prednisone Overview Over
Slide 17: SGX201 for Acute Radiation Enteritis
SGX201 for Acute Radiation Enteritis Proprietary time-release formulation of oral BDP Designed to block inflammatory component of radiation enteritis in Gl tract of cancer patients receiving pelvic radiation therapy Phase 1/2 open label, dose-ranging study completed in 16 subjects across five center
Slide 18: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government SOLIGENIX,
Slide 19: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease ThermoVax™™ Heat Stabilization Platform BioDefense Vaccines RiVax™ Ricin Vaccine Soligenix Vaccine | BioDefense Division ® OrbeShield™ Gastrointestinal Acute Funded by Government (Oral BDP Radiation Syndrot Therapeutic) (GIARS) Melioidosis
Slide 20: ThermoVax — Vaccine Thermostability Platform
ThermoVax™ — Vaccine Thermostability Platform Overview Market Opportunity Development Plan Dried vaccine with desirable physical and immunogenic properties Improved stability and shelf-life at temperatures exceeding 40°C Positive Proof of Concept achieved — 6 months stability data with no degradatio
Slide 21: RiVax — Ricin Toxin Vaccine
RiVax™— Ricin Toxin Vaccine Produced as aluminum-adsorbed vaccine Effectiveness observed against all routes of toxin exposure Non-human primate pilot efficacy studies demonstrated induction of neutralizing antibodies and protection against aerosol exposure Phase 1 studies demonstrated safety, induct
Slide 22: OrbeShield for GI ARS
OrbeShield™ for GI ARS Proprietary two tablet immediate and delayed release BDP formulation Multiple commercial scale cGMP batches manufactured with long-term controlled room temperature stability Overview Statistically significant survival post radiation exposure versus controls in canine model of
Slide 23: SGX1071 for Melioidosis
SGX1071 for Melioidosis Overview Melioidosis is caused by Burkholderia pseudomallei (Bps) Frequently resistant to antibiotic treatment High mortality and relapse rate, despite prolonged therapy Exclusive Channel Collaboration with Intrexon Corporation Development of human monoclonal antibody (mAb) t
Slide 24: Significant Worldwide Market Potential
Significant WWW Market Potential $ Millions ‘SGx942 Oral Mucositis (CSOLIGENIX, ‘SGX203 Pediatric Crohn's Disease SGx201 ‘Acute Radiation Enteritis orBec™ Chronic GVHD Treatment Rivax™ VeloThrax™ OrbeShield™ Ricin Vaccine Anthrax Vaccine Gl Acute Radiation ‘Syndrome Assumptions) Oral Mucositis in H&
Slide 25: Investment Highlights
Investment Highlights » Diverse pipeline with nine (9) potential value drivers in development © Innovative products addressing high unmet medical needs o Experienced management and Board of Directors © Expertise in specialized development areas of GI, cancer supportive care and biodefense © Potentia
Slide 26: Thank You
me a“ THANK YOU